Cytokinetics traded at $44.56 this Thursday February 2nd, increasing $1.73 or 4.04 percent since the previous trading session. Looking back, over the last four weeks, Cytokinetics gained 0.47 percent. Over the last 12 months, its price rose by 38.86 percent. Looking ahead, we forecast Cytokinetics to be priced at 41.71 by the end of this quarter and at 37.73 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
43.70
Daily Change
-1.93%
Yearly
36.18%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Eisai 7,869.00 -66.00 -0.83% 36.69%
Arca Biopharma 2.26 0.03 1.42% 21.59%
Acadia Pharmaceuticals 19.80 -0.11 -0.55% -16.10%
Acorda Therapeutics 1.03 0.05 5.59% -45.65%
Amgen 243.34 -3.19 -1.29% 9.56%
Bayer 56.56 -0.24 -0.42% 7.49%
Brainstorm Cell Therapeutics 2.20 0.10 4.71% -27.90%
Biogen 287.35 -0.18 -0.06% 29.71%
Bristol-Myers Squibb 73.14 0.37 0.51% 12.54%
Capricor Therapeutics 4.28 0.08 1.79% 3.51%
Cytokinetics 43.70 -0.86 -1.93% 36.18%
Exelixis 17.62 0.01 0.06% -1.84%
Geron 3.34 -0.04 -1.18% 237.37%
Halozyme Therapeutics 52.87 0.70 1.34% 54.14%
Ionis Pharmaceuticals 41.20 1.17 2.92% 32.60%
Intra Cellular Therapies 49.74 1.92 4.02% 7.43%
Ligand Pharmaceuticals 70.05 -0.60 -0.85% -41.35%
Eli Lilly 337.60 6.90 2.09% 39.35%
Merck & Co 103.07 -0.39 -0.38% 31.20%
Novartis 79.84 1.58 2.02% 0%
Pfizer 44.05 -0.29 -0.65% -16.89%
Regeneron Pharmaceuticals 778.00 26.80 3.57% 24.89%
Roche Holding 283.30 9.45 3.45% -17.94%
Sanofi 84.67 -2.10 -2.42% -6.22%

Indexes Price Day Year
USND 12182 -19.23 -0.16% -13.59%
US2000 1999 -2.20 -0.11% -0.17%

Cytokinetics
Cytokinetics, Incorporated is a late-stage biopharmaceutical company that is focused on discovering, developing and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases. The Company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. The Company is conducting METEORIC-HF, a second Phase III clinical trial of omecamtiv mecarbil. It is also developing aficamten, a cardiac myosin inhibitor, for the potential treatment of HCM. The Company also conducts research and development on novel treatments for disorders involving muscle function beyond muscle contractility. The Company’s lead drug candidates in clinical development are omecamtiv mecarbil, a cardiac myosin activator; CK-136, a cardiac troponin activator; reldesemtiv, a fast-skeletal muscle troponin activator (FSTA) and CK-3773274 (CK-274), a cardiac myosin inhibitor.